(1999) 51 Suppl 3:1048
Clinical trials tested doses ranging from 250mcg to 1mg daily, with most protocols settling around 300-500mcg for optimal fat metabolism support
Therefore, RLS symptoms emerging during semaglutide treatment may represent the natural progression of diabetic complications rather than a drug-induced effect
Many of the members who voted against adding the other six peptides to the 503A Bulks List argued that there are still significant unknowns around the effectiveness and potential risks of those drugs, too
9,12,17 Remaining questions include the longer-term efficacy and safety of these agents, as well as their efficacy and safety in additional populations, including geriatric patients, pediatric patients, or overweight but non-obese adults without comorbidities
Under brand names like Wegovy, specifically for weight loss, and Ozempic, for type 2 diabetes, semaglutide has gained popularity